The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases: Results of a randomized phase II A-PLUS trial.
 
Yen-Shen Lu
Honoraria - Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Research Funding - Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Eisai; Novartis; Pfizer; Roche
 
Ming-Shen Dai
No Relationships to Disclose
 
Ling-Ming Tseng
No Relationships to Disclose
 
Shin-Cheh Chen
No Relationships to Disclose
 
Wei-Wu Tom Chen
No Relationships to Disclose
 
Tsu-Yi Chao
No Relationships to Disclose
 
Ta-Chung Chao
No Relationships to Disclose
 
Yuan-Ching Chang
No Relationships to Disclose
 
Chang-Fang Chiu
No Relationships to Disclose
 
Chien-Ting Liu
No Relationships to Disclose
 
Chingh-Hung Lin
No Relationships to Disclose
 
Chun-Yu Liu
No Relationships to Disclose
 
Ya-Fang Chen
No Relationships to Disclose
 
Twan Ying Chang
No Relationships to Disclose
 
Jyh-Cherng Yu
No Relationships to Disclose
 
Kun-Ming Rau
No Relationships to Disclose
 
Yao-yu Hsieh
No Relationships to Disclose
 
Shih-Che Shen
No Relationships to Disclose
 
Shu-Min Huang
No Relationships to Disclose
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche; Lilly
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; CSR Pharma; Eisai; Genentech/Roche; IQVIA; MSD; Novartis; Ono Pharmaceutical